# Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

> **NCT00523211** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 506 (actual)

## Conditions studied

- HIV Infections
- Acquired Immunodeficiency Syndrome

## Interventions

- **DRUG:** Vicriviroc
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00523211
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-06
- **Final completion:** 2011-03
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2015-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523211, "Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00523211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*